TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must be 4 - 17 years of age.~* Subject must have a diagnosis of type 1 or type 2 diabetes mellitus for at least 3 months prior to enrollment.~* Subject is currently using SMBG for managing their diabetes.~* Subject and/or caregiver must be able to read and understand English .~* In the investigator's opinion, the subject and/or caregiver must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.~* Subject and/or caregiver must have access to an internet connected computer for uploading data from the blood glucose meter and FreeStyle Libre system.~* Subject must have an overnight companion (caregiver 18 years or older) present in the same home during participation of the study.~* Subject and/or parent or guardian must be willing and able to provide written signed and dated informed consent and assent when appropriate.~Exclusion Criteria:~* Subject and/or caregiver is a member of the Site Staff.~* Subject is currently using or has previously used a continuous glucose monitoring system for managing their diabetes~* Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.~* Subject is known to be pregnant or is attempting to become pregnant at the time of enrollment.~* Subject is on dialysis at the time of enrollment.~* Subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff.~* Subject currently is participating in another clinical trial.~* Subject is unsuitable for participation due to any other cause as determined by the Investigator.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- SMBG/FreeStyle Libre (Type: None): During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Sunitinib for Refractory Malignant Ascites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumor malignancy and failure of at least one biologic or cytotoxic regimen, or the inability to receive standard treatment due to performance status (PS\>2).~* Ascites based on paracentesis or CT scan within one month prior to enrollment~* Life expectancy \> 3 months~* Indwelling paracentesis catheters are permitted, paracentesis is permitted at the investigators discretion~* Negative urine pregnancy test for females~* All subjects must agree to use birth control~* All subjects must abstain from eating grapefruit and grapefruit juice. They must tell their physicians about any changes in their medication including over-the-counter and herbal supplements.~Exclusion Criteria:~* History of congestive heart failure~* Creatinine \> 2.0~* Pregnant or nursing~* ALT \> 2.5 times the upper limit of normal~* Blood pressure \> 160/90 (antihypertensives permitted)~* Gastrointestinal or intra-abdominal hemorrhage within the last 6 months~* History of QTc \> 450 milliseconds~* Brain metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trident II Revision Outcomes Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.~B. Patient is a male or non-pregnant female age 18-85 years of age at the time of study device implantation.~C. Patient is a candidate for a revision of a failed acetabular component with a cementless acetabular component.~D. Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations.~Exclusion Criteria:~E. Patient has a Body Mass Index (BMI) \> 45. F. Patient is diagnosed with Inflammatory Arthritis. G. Patient has a non-Stryker retained stem. H. Patient has an active or suspected latent infection in or about the affected hip joint at time of study device implantation.~I. Patient has a mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.~J. Patient has compromised bone stock which cannot provide adequate support and/or fixation to the prosthesis.~K. Patient is diagnosed with a systemic disease (e.g. Lupus Erythematosus) or a metabolic disorder (e.g. Paget's Disease) leading to progressive bone deterioration.~L. Patient is immunologically suppressed or receiving steroids in excess of normal physiological requirements (e.g. \> 30 days). M. Patient has a known sensitivity to device materials. N. Patient is a prisoner.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Trident II Tritanium Acetabular Shell for Revision (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Individualised Informal Caregiver Training for Palliative Care at Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient currently at home, reliant on family/friends (lay carers) some or all of the time to help with practical or personal care.~* The carer is aged 18 years or over.~* The carer and the patient have the capacity to consent to being involved in the study.~Exclusion Criteria:~* There is a current plan in place for all care to be provided by paid carers full time.~* The patient currently receiving more than one contact with Hospice Specialist Occupational Therapy or is likely to develop needs requiring more than one contact Hospice Occupational Therapy over the four week study intervention period.~* Patients and carers who are not able to speak or understand adequate English for consent to be obtained, to be able to undertake carer training and to complete the study outcome measures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caregiver Training (Type: EXPERIMENTAL): Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice.
- Usual Care (Type: NO_INTERVENTION): On-going usual care from multi-professional team at hospice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer~  * Stage I, II, III (T1-4, N0-3, M0)~    * No metastases to supraclavicular, contralateral hilar, or contralateral scalene lymph nodes~ * Medically inoperable or unresectable~* No pleural or pericardial effusion (except with repeated negative cytology)~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0 or 1~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 4,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 6.8 g/dL~* No hemoptysis causing a decrease of hemoglobin of 1 g/dL or more within 24 hours~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 1.25 times normal OR~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No evidence of heart failure~* No myocardial infarction within the past 6 months~* No superior vena cava syndrome~Pulmonary:~* FEV1 at least 1 L~* No pre-existing fibrotic lung disease~* No postobstructive pneumonia preventing exact delineation of tumor volume~* Diffusion capacity at least 60%~Other:~* No weight loss of more than 10% in the past 3 months~* No uncontrolled infection~* No serious medical risk factors involving any of the major organ systems that would preclude adherence to the study treatment schedule~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy~Chemotherapy:~* No prior chemotherapy~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the chest~* Maximum length of the esophagus receiving 40 Gy no greater than 18 cm~* Maximum length of the esophagus receiving 66 Gy no greater than 12 cm~* Must limit the spinal cord dose to a maximum of 50 Gy~* Must be able to exclude 25% of the heart from the boost volume~Surgery:~* Not specified~Other:~* No other concurrent experimental medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transversus Abdominis Plane Block for Pain Relieve in Children Undergoing Groin Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female children aged 2 - 8 years~* physical status classification system (ASA) score I or II~* Undergoing surgical interventions in the groin (hernia repair, funiculocele ectomy)~Exclusion Criteria:~* Hypersensitivity to Levobupivacaine

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Study Arms:
- transversus abdominal plane block (Type: EXPERIMENTAL): Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pathology of Helicases and Premature Aging: Study by Derivation of hiPS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patinet with one of the 3 helicase-associated precoce aging desease~Exclusion Criteria:~* Minor and /or mentally incapable patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Taking of cutaneous cells by biopsy (Type: None): Taking of cutaneous cells by biopsy and a sample of blood

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peri-operative Aspirin Continuation Versus Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults aged 18 years and older with the ability for self-consent,~* referred for elective TURBT,~* receiving low-dose daily Aspirin prophylaxis.~Exclusion Criteria:~* known coagulopathy or abnormal coagulation profile (prothrombin time, partial thromboplastin time, or platelet count),~* receiving other anti-thrombotic, anti-coagulant, or non-steroidal anti-inflammatory medication (NSAIDs),~* pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin continuation (Type: ACTIVE_COMPARATOR): Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
- Aspirin discontinuation (Type: NO_INTERVENTION): Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Absence of symptomatic UTI~3. Absence of upper/lower tract obstructions~4. No known allergies to the study products~5. Willing to comply with all study procedures and available for the duration of the study~Exclusion Criteria:~1. 17 years or younger~2. Symptomatic UTI~3. Presence of upper/lower tract obstructions~4. Known allergic reaction to the study products~5. Unable to provide signed and dated informed consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLASTX Lubricated Catheter (Type: EXPERIMENTAL): Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
- McKesson Jelly Lubricated Catheter (Type: PLACEBO_COMPARATOR): Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult ADPKD patients aged 18-70~* combined kidney volume \>1200 ml~* estimated creatinine clearance \>60 ml/min~* absence of implanted ferromagnetic objects~Exclusion Criteria:~* Age \>70~* uncontrolled hyperlipidemia~* Proteinuria \>500 mg/day~* unstable cerebral aneurysm~* active coronary artery disease~* diagnosis of another systemic condition affecting kidney function (ie: diabetes, hepatitis B or C, HIV)~* diagnosis of cancer other than skin cancer~* pregnancy or lactation~* presence of implanted ferromagnetic objects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Rapamycin (Type: EXPERIMENTAL): Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
- Standard of Care-Placebo (Type: PLACEBO_COMPARATOR): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Treatment of Leg Fractures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subject who is 18 years of age or older at the time of signing the informed consent.~2. Subject provides an Institutional Review Board (IRB)-approved informed consent. The subject must have the physical and mental capacity to provide informed consent for him/herself.~3. Subject has experienced proximal tibial fracture (OTA Type 41 A-C) or distal tibial fracture (OTA 43 Type A-C) with or without fibular/malleolar involvement (OTA 44 A-C) and are scheduled for ORIF using the EVOS SMALL Plating System.~4. Subject is willing and able to attend all study visits including 1 year post-operative follow-up.~Exclusion Criteria:~1. Subject has contraindications or hypersensitivity to the use of the EVOS SMALL Plating System or its components (316L stainless steel).~2. Subject has a physical condition that, in the opinion of the Investigator, would preclude adequate implant support or retard healing, such as blood supply impairment, insufficient bone quality or quantity, previous infection, obesity, severe bow or gross bony distortion of the tibia, as detailed in the IFU.~3. Subject has, in the opinion of the Investigator, an emotional or neurologic condition that precludes cooperation and compliance with the rehabilitation regimen.~4. Subject is currently in another investigational drug, biologic, or device study or has been treated with an investigational product within the last 30 days.~5. Subject is known to be at risk for loss to follow-up, or failure to return for scheduled visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Treatment (Type: None): EVOS SMALL PLating System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stroke~* lesion age at least 6 months~* aphasia with at least moderate severity according to Aachener Aphasia Test (AAT)~* age between 40 and 75~* German-speaking (at a native speaking level)~Exclusion Criteria:~* cognitive or speech-language therapy during the 2-weeks stimulation course~* intensive language training when exceeding 1 hour, 2 times a week during the 2-weeks stimulation course and the follow-up period (60 days after stimulation was completed)~* additional neurological diseases, e.g. surgical brain tumor removal, untreated tumor disease, acute traumatic brain injury, and/or craniotomy~* (severe) dysarthria~* untreated hypertension exceeding 160/100 mmHg (patients with treated hypertension and blood pressure below 160/100 mmHg can be included)~* increased risk of vascular thrombosis~* epilepsy, photo sensitivity, acute focal findings (patients without focal findings or epileptiform discharges can be included when they had only a single seizure more than 10 years ago)~* dementias and neurodegenerative diseases~* significant psychiatric disturbances, e.g. schizophrenia~* major attention and/or memory deficits~* major hearing loss~* patients with uncorrected visual deficits~* severe global aphasia~* modality-specific disorders (pure speech apraxia, pure alexia, pure agraphia)~* electric or electronic implants (e.g. heart pacemakers)~* metal artefacts located at the head~* medication with impact on the central nervous system (e.g. antidepressant or sedative drugs)~* participation in another trial~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Verum stimulation (Type: EXPERIMENTAL): repetitive transorbital alternating current stimulation (rtACS)
- Placebo stimulation (Type: SHAM_COMPARATOR): Sham stimulation (placebo condition) no intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues